Literature DB >> 24508508

Rapamycin: one drug, many effects.

Jing Li1, Sang Gyun Kim1, John Blenis2.   

Abstract

The mammalian target of rapamycin (mTOR) signaling pathway is a master regulator of cell growth and metabolism. Deregulation of the mTOR pathway has been implicated in a number of human diseases such as cancer, diabetes, obesity, neurological diseases, and genetic disorders. Rapamycin, a specific inhibitor of mTOR, has been shown to be useful in the treatment of certain diseases. Here we discuss its mechanism of action and highlight recent findings regarding the effects and limitations of rapamycin monotherapy and the potential utility of combination therapy with rapamycin.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24508508      PMCID： PMC3972801          DOI： 10.1016/j.cmet.2014.01.001

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  45 in total

1.  Rapamycin inhibits mTORC1, but not completely.

Authors:  Carson C Thoreen; David M Sabatini
Journal:  Autophagy       Date:  2009-07-22       Impact factor: 16.016

2.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.

Authors:  Andrew Y Choo; Sang-Oh Yoon; Sang Gyun Kim; Philippe P Roux; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

3.  PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase.

Authors:  J Chung; T C Grammer; K P Lemon; A Kazlauskas; J Blenis
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

4.  Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase.

Authors:  D J Price; J R Grove; V Calvo; J Avruch; B E Bierer
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

5.  Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice.

Authors:  Geng-Ruei Chang; Yi-Shin Chiu; Ying-Ying Wu; Wen-Ying Chen; Jiunn-Wang Liao; Te-Hsin Chao; Frank Chiahung Mao
Journal:  J Pharmacol Sci       Date:  2009-04       Impact factor: 3.337

6.  mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes.

Authors:  Merav Fraenkel; Mali Ketzinel-Gilad; Yafa Ariav; Orit Pappo; Melis Karaca; Julien Castel; Marie-France Berthault; Christophe Magnan; Erol Cerasi; Nurit Kaiser; Gil Leibowitz
Journal:  Diabetes       Date:  2008-01-03       Impact factor: 9.461

7.  Rapamycin treatment for a child with germline PTEN mutation.

Authors:  Deborah J Marsh; Toby N Trahair; Janet L Martin; Wey Yeeng Chee; Jan Walker; Edwin P Kirk; Robert C Baxter; Glenn M Marshall
Journal:  Nat Clin Pract Oncol       Date:  2008-04-22

8.  Rapamycin reduces seizure frequency in tuberous sclerosis complex.

Authors:  Jennifer Muncy; Ian J Butler; Mary Kay Koenig
Journal:  J Child Neurol       Date:  2009-01-16       Impact factor: 1.987

Review 9.  Molecular mechanisms of mTOR-mediated translational control.

Authors:  Xiaoju Max Ma; John Blenis
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04-02       Impact factor: 94.444

10.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

Authors:  John J Bissler; Francis X McCormack; Lisa R Young; Jean M Elwing; Gail Chuck; Jennifer M Leonard; Vincent J Schmithorst; Tal Laor; Alan S Brody; Judy Bean; Shelia Salisbury; David N Franz
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245
View more
  359 in total

Review 1.  Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.

Authors:  Priyanka Singh; Veerandra Kumar; Sonu Kumar Gupta; Gudia Kumari; Malkhey Verma
Journal:  Med Oncol       Date:  2021-01-16       Impact factor: 3.064

2.  Negative Conditioning of Mitochondrial Dysfunction in Age-related Neurodegenerative Diseases.

Authors:  Sharmelee Selvaraji; Luting Poh; Venkateswaran Natarajan; Karthik Mallilankaraman; Thiruma V Arumugam
Journal:  Cond Med       Date:  2019-02

3.  Design, Synthesis, and Evaluation of Novel 3-Carboranyl-1,8-Naphthalimide Derivatives as Potential Anticancer Agents.

Authors:  Sebastian Rykowski; Dorota Gurda-Woźna; Marta Orlicka-Płocka; Agnieszka Fedoruk-Wyszomirska; Małgorzata Giel-Pietraszuk; Eliza Wyszko; Aleksandra Kowalczyk; Paweł Stączek; Andrzej Bak; Agnieszka Kiliszek; Wojciech Rypniewski; Agnieszka B Olejniczak
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

4.  IPF pathogenesis is dependent upon TGFβ induction of IGF-1.

Authors:  Danielle M Hernandez; Jeong-Han Kang; Malay Choudhury; Mahefatiana Andrianifahanana; Xueqian Yin; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2020-02-17       Impact factor: 5.191

Review 5.  The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus.

Authors:  Tomohiro Suhara; Yuichi Baba; Briana K Shimada; Jason K Higa; Takashi Matsui
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

6.  mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease.

Authors:  Andrés Norambuena; Horst Wallrabe; Lloyd McMahon; Antonia Silva; Eric Swanson; Shahzad S Khan; Daniel Baerthlein; Erin Kodis; Salvatore Oddo; James W Mandell; George S Bloom
Journal:  Alzheimers Dement       Date:  2016-09-29       Impact factor: 21.566

Review 7.  Metabolic control of autophagy.

Authors:  Lorenzo Galluzzi; Federico Pietrocola; Beth Levine; Guido Kroemer
Journal:  Cell       Date:  2014-12-04       Impact factor: 41.582

8.  Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism.

Authors:  Arti B Patel; Irene Tsilioni; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

9.  A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.

Authors:  Johan Törlén; Olle Ringdén; Karin Garming-Legert; Per Ljungman; Jacek Winiarski; Kari Remes; Maija Itälä-Remes; Mats Remberger; Jonas Mattsson
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

10.  Emerging role of mTOR in the response to cancer therapeutics.

Authors:  Erika Ilagan; Brendan D Manning
Journal:  Trends Cancer       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.